Merck, Ablynx partner to develop Nanobody candidates
As a part of the agreement, Ablynx will be responsible for the discovery of Nanobody candidates while Merck will be responsible for the research, development, manufacturing and commercialisation
The European Commission (EC) has approved an extended use of Johnson & Johnson’s Tecvayli (teclistamab), along with daratumumab, to treat adult patients with relapsed or refractory multiple myeloma (r/r MM).